Legislating against use of cost-effectiveness information.
about
The economic burden of disease by industry: differences in quality-adjusted life years and associated costsThe use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of CardioCost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs.Ethical priority setting for universal health coverage: challenges in deciding upon fair distribution of health servicesCurrent challenges in health economic modeling of cancer therapies: a research inquiry.Assessment of the cost-effectiveness and clinical outcomes of a fourth-generation synchronous telehealth program for the management of chronic cardiovascular disease.Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.Hurdles and delays in access to anti-cancer drugs in Europe.Integrating economic evaluation methods into clinical and translational science award consortium comparative effectiveness educational goals.Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparitiesPatient education for alcohol cessation intervention at the time of acute fracture surgery: study protocol for a randomised clinical multi-centre trial on a gold standard programme (Scand-Ankle)Cost utility analysis of reverse total shoulder arthroplasty.Valuation of Child Behavioral Problems from the Perspective of US Adults.Cost-effectiveness Assessment of Cardiac Interventions: Determining a Socially Acceptable Cost Threshold.Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.Pleurodesis with Thulium Cyber Laser versus talc poudrage: a comparative experimental study.The ethics and reality of rationing in medicineCost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease.Quality of life as an outcome of opioid use disorder treatment: A systematic review.Ethical Dilemmas in Postnatal Treatment of Severe Congenital HydrocephalusCapsule Commentary on Michaelidis et al., Cost-Effectiveness of Decision Support Strategies in Acute Bronchitis.Comparative effectiveness research in cancer: what has been funded and what knowledge gaps remain?The Effect of Budgetary Restrictions on Breast Cancer Diagnostic DecisionsHTA Implementation Roadmap in Central and Eastern European Countries.Health Economics Information in Wound Care: The Elephant in the RoomThe economic value of personalized medicine tests: what we know and what we need to know.Getting to value in neurological care: a roadmap for academic neurology.The debate over health care rationing: Déjà vu all over again?Principles for planning and conducting comparative effectiveness research.Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): an overview and update for the cytopathologist.A review of economic factors related to the delivery of health care for chronic low back pain.Cost analysis of postmastectomy reconstruction: A comparison of two staged implant reconstruction using tissue expander and acellular dermal matrix with abdominal-based perforator free flaps.Bending the Cost Curve-Establishing Value in Spine Surgery.The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.Assessing the Quality of Economic Evaluations of FDA Novel Drug Approvals: A Systematic Review.Shaking Up the Debate: Ensuring the Ethical Use of DBS Intervention Criteria for Mid-Stage Parkinson's Patients.Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.Reducing branded prescription drug prices: A review of policy options.The lag from FDA approval to published cost-utility evidence.
P2860
Q23911875-B8C716A2-6400-4898-BBBE-9E76B64C0D40Q26861465-F65E391D-DC67-4729-84D5-28D63377A68EQ28077393-1B9D1691-C346-48FF-853E-4245CCEE6D13Q28394094-5EC99736-9BE6-4889-A808-2231829D0EB5Q33805471-8DDCE9C7-589C-4F6B-BFDB-AAB48502147EQ33807769-8BE2FA33-76E2-486E-A838-68DE35633C66Q34232330-2B6E5F6C-E54B-46F2-B2EF-70AAD5F55192Q34680656-3351E5BB-8023-4B7D-A918-2223E464FEF6Q35010854-382F0ED5-BB70-45F4-8451-137B9FDE7ACEQ35223397-1E0F0ECF-2AB6-4A66-AC6F-AE3BB0184029Q35576408-CDFF879C-24AB-4CD5-84C3-B15FFB7E2519Q35633834-0116881F-3393-4D6F-9D7A-A9D8D7232EFDQ35713154-BE9CC4FE-BF4E-42F3-BBDC-567C9DBFB421Q35795256-EB6563F6-2677-407C-AF92-C95643A21DCFQ35952231-94822C3E-F8F1-44A5-AF10-8410428E293FQ36066699-50502D93-3950-4345-A6A8-E7B2F765BFF3Q36151668-7AD130AF-1BE0-4949-B40D-CFFBBAC4E2E6Q36204864-DF668919-8898-4BA7-9A70-184798DB79D4Q36278101-EB80D23A-E734-4FB6-9293-2304F7C63D46Q36486031-37E4DC4E-8AB9-4324-AC12-DB582395E9D3Q36604904-4937C34E-C623-4D56-9BD9-B2D42329BD42Q36953584-6CEF06CB-ADAB-498E-A831-140E2150D504Q37156553-CB03366A-7E6F-4968-8518-1B060EBDAE0DQ37343970-FC44FF8A-BDBF-429E-9B3D-08BDD884C273Q37398186-44F4ABB8-6223-4FD7-95C6-3E898DA52A33Q37629385-E630B5B6-C730-4C47-B8A2-8B1168D5EDDBQ37890984-6DAEF8CD-7607-484C-99D4-A718FAB2FAB4Q38038855-23EBE12E-3266-4430-9BA9-075FCA947717Q38162853-CA2FC216-38E2-40AC-B1D4-0BB9A115A59BQ38206743-FDB95A03-1296-4502-AE0C-58DC3B731B83Q38268038-6531F03D-F935-4AFF-9CE3-951993CAAF30Q38737850-AE5E67FA-86D5-44CB-B3B8-3A6D2DB8545AQ38870886-019570C3-FD34-4DD6-B67B-4A244017FE78Q38885867-85E5403E-660F-41B0-9E9B-3392F11E6916Q38917745-B0729CAD-C0D8-41B1-AD82-2FFADACFB7E9Q39301896-683641FC-8092-48A1-9A44-6F78C1591514Q39365268-64489776-BE2D-4C1A-8B6A-1E391AF8D160Q39912396-C8836B56-B9E8-47E7-A242-3C0855F8AB1FQ40083993-A078E43E-267B-4223-A4AA-4FD6177D8621Q41595205-974D7766-9354-49AA-A962-BD92A35AF5AC
P2860
Legislating against use of cost-effectiveness information.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Legislating against use of cost-effectiveness information.
@ast
Legislating against use of cost-effectiveness information.
@en
Legislating against use of cost-effectiveness information.
@nl
type
label
Legislating against use of cost-effectiveness information.
@ast
Legislating against use of cost-effectiveness information.
@en
Legislating against use of cost-effectiveness information.
@nl
prefLabel
Legislating against use of cost-effectiveness information.
@ast
Legislating against use of cost-effectiveness information.
@en
Legislating against use of cost-effectiveness information.
@nl
P356
P1476
Legislating against use of cost-effectiveness information.
@en
P2093
Peter J Neumann
P304
P356
10.1056/NEJMP1007168
P407
P577
2010-10-01T00:00:00Z